Oberland Capital is also backing MeiraGTx with structured payments to help bring two late-stage gene therapies to commercialization, extending the funding runway at a time when approvals for AAV-based rare disease programs remain tightly linked to milestone execution. The financing ties cash tranches to completion of Phase II results and to FDA approval events, with low single-digit capped royalties on included assets. MeiraGTx previously reacquired bota-vec (botaretigene sparoparvovec) from Johnson & Johnson after a phase 3 miss in X-linked retinitis pigmentosa (XLRP), while the company continues advancing AAV2-hAQP1 for radiation-induced xerostomia. Under the Oberland structure, the initial $135 million includes both royalty-based consideration and an equity component. Company officials said additional tranches could be added if MeiraGTx meets regulatory milestones or achieves positive trial readouts tied to dry mouth outcomes.